The cost-effectiveness of treatment with desloratadine in patients with persistent allergic rhinitis

Current Medical Research and Opinion

Volumn 26, Issue 6, 2010, Pages 1389-1397

  Sullivan, Patrick W ^a   Navaratnam, Prakash ^b   Lorber, Richard ^c   Shekar, Tulin ^c  

^a REGIS UNIVERSITY   (United States)

^b Informagenics LLC   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Allergic; Cost effectiveness analysis; Costbenefit analysis; Desloratadine; Histamine H1 antagonists; Non sedating; Perennial; Rhinitis

Indexed keywords

DESLORATADINE; PLACEBO;

ABSENTEEISM; ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DECISION MAKING; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MALE; MULTICENTER STUDY; PERENNIAL RHINITIS; PRODUCTIVITY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; SCHOOL CHILD; SCORING SYSTEM; SENSITIVITY ANALYSIS; SIMULATION; SYMPTOM; VISUAL ANALOG SCALE;

ADOLESCENT; COST-BENEFIT ANALYSIS; FEMALE; FRANCE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LORATADINE; MALE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHINITIS, ALLERGIC, SEASONAL; YOUNG ADULT;

EID: 77952490750     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003750381     Document Type: Article

References (38)

1. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy;63(Suppl. 86):8-160
2. Bousquet J, Van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(5 Suppl.):S147-334
3. Bousquet J, Neukirch F, Bousquet PJ, et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol 2006;117:158-162
4. Demoly P, Allaert FA, Lecasble M, et al. Validation of the classification of ARIA (allergic rhinitis and its impact on asthma). Allergy 2003;58:672-675
5. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24:758-764
6. Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy 2005;60:350-353
7. Bachert C, Bousquet J, Canonica GW, et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004;114:838-844
8. Canonica GW, Bousquet J, Mullol J, et al. A survey of the burden of allergic rhinitis in Europe. Allergy 2007;62(Suppl. 85):17-25
9. Bousquet PJ, Bousquet-Rouanet L, Co Minh HB, et al. ARIA (Allergic Rhinitis and Its Impact on Asthma) classification of allergic rhinitis severity in clinical practice in France. Int Arch Allergy Immunol 2007;143:163-169
10. Simoens S, Laekeman G. Pharmacotherapy of allergic rhinitis: a pharmaco-economic approach. Allergy 2009;64:85-95
11. Reed SD, Lee TA, McCrory DC. The economic burden of allergic rhinitis: a critical evaluation of the literature. Pharmacoeconomics 2004;22:345-361
12. Schoenwetter WF, Dupclay Jr L, Appajosyula S, et al. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin 2004; 20:305-317
13. Statistics BoL. Bureau of Labor Statistics Consumer Price Index, 2008. Available at: http://www.bls.gov/data/#prices [Last accessed 26 March 2009]
14. Statistics BoL. Bureau of Labor Statistics Employment Cost Index, 2008. Available at: http://www.bls.gov/data/#wages [Last accessed 26 March 2009]
15. Law AW, Reed SD, Sundy JS, et al. Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey. J Allergy Clin Immunol 2003;111:296-300
16. Malone DC, Lawson KA, Smith DH, et al. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997;99(1 Pt 1):22-27
17. McMenamin P. Costs of hay fever in the United States in 1990 [see comment]. Ann Allergy 1994;73:35-39
18. Lamb CE, Ratner PH, Johnson CE, et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin 2006;22:1203-1210
19. Dessi P, Allaert FA, Urbinelli R, et al. [Medico-economic aspects of the management of perennial allergic rhinitis in general medicine]. Allerg Immunol (Paris) 1998;30:277-283
20. Bousquet J, Demarteau N, Mullol J, et al. Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy 2005;60:788-794
21. Drummond MF. Methods for the Economic Evaluation of Health Care Programmes, 2nd edn. Oxford; New York: Oxford University Press, 1997
22. Bachert C. A review of the efficacy of desloratadine, fexofenadine, and levo-cetirizine in the treatment of nasal congestion in patients with allergic rhinitis. Clin Ther 2009;31:921-944
23. Ciprandi G, Cirillo I, Vizzaccaro A, et al. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol 2005;5:1800-1808
24. Devillier P, Roche N, Faisy C. Clinical pharmacokinetics and pharmacody-namics of desloratadine, fexofenadine and levocetirizine: a comparative review. Clin Pharmacokinet 2008;47:217-230
25. VIDAL. VIDALpro Medicaments. VIDALpro, 2008. Available at: http://www. vidalpro.net/Medicaments/Front/recherchemedic.asp?site-2&cartouche- 17&id-40668&lib-AERIUS\+5mg\+cp\+pellic\+%3A\+B%2F15&type-pa- spe [Last accessed 3 December 2008]
26. Lamel. l'assurance maladie en ligne (ameli). Tarifs conventionnels des mé decins gé néralistes, 2008. Available at: http://www.ameli.fr/professionnels-de-sante/medecins/votre-convention/tarifs/ tarifs-conventionnels-des-medecins-generalistes/tarifs-des-medecins- generalistes-en-metropole. php?&page-2 [Last accessed 3 December 2008]
27. économiques Indlsedé. Institut national de la statistique et des études écon-omiques. Indice des prix à la consommation y compris tabac 2008. Available at: http://www.insee.fr/fr/themes/ conjoncture/historique-ipc.asp [Last accessed 3 December 2008]
28. économiques Indlsedé. Institut national de la statistique et des études écon-omiques. Salaires dans le privé en 2006: en moyenne, 2583 E bruts par mois, 2008. Available at: http://www.insee.fr/fr/ themes/document.asp? reg-id-0&ref-id-ip1174#inter1 [Last accessed 3 December 2008]
29. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17:479-500
30. Briggs AH, Ades AE, Price MJ. Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework. Med Decis Making 2003;23:341-350
31. Briggs AH, Goeree R, Blackhouse G, et al. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastro-esophageal reflux disease. Med Decis Making 2002;22:290-308
32. Ciprandi G, Tosca M, Passalacqua G, et al. Long-term cetirizine treatment reduces allergic symptoms and drug prescriptions in children with mite allergy. Ann Allergy Asthma Immunol 2001;87:222-226
33. Sullivan PW, Follin SL, Nichol MB. Cost-benefit analysis of first-generation antihistamines in the treatment of allergic rhinitis. Pharmacoeconomics 2004;22:929-942
34. Sullivan PW, Follin SL, Nichol MB. Transitioning the second-generation anti-histamines to over-the-counter status: a cost-effectiveness analysis. Medical Care 2003;41:1382-1395
35. Keith PK, Haddon J, Birch S. A cost-benefit analysis using a willingness-to-pay questionnaire of intranasal budesonide for seasonal allergic rhinitis. Rhinocort Study Group. Ann Allergy Asthma Immunol 2000;84:55-62
36. Kozma CM, Sadik MK, Watrous ML. Economic outcomes for the treatment of allergic rhinitis. Pharmacoeconomics 1996;10:4-13
37. Lange B, Lukat KF, Rettig K, et al. Efficacy, cost-effectiveness, and tolerability of mometasone furoate, levocabastine, and disodium cromoglycate nasal sprays in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2005;95:272-282
38. Stahl E, van Rompay W, Wang EC, et al. Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol 2000;84:397-402